97 related articles for article (PubMed ID: 20723974)
21. Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the disease.
Valent P
Br J Haematol; 2008 Jul; 142(3):361-78. PubMed ID: 18540942
[TBL] [Abstract][Full Text] [Related]
22. Overcoming drug resistance in chronic myeloid leukemia.
Cortes J
Curr Opin Hematol; 2006 Mar; 13(2):79-86. PubMed ID: 16456373
[TBL] [Abstract][Full Text] [Related]
23. Synergistic activity of the Src/Abl inhibitor bosutinib in combination with imatinib.
Redaelli S; Boschelli F; Perini P; Pirola A; Viltadi M; Gambacorti-Passerini C
Leukemia; 2010 Jun; 24(6):1223-7. PubMed ID: 20445575
[No Abstract] [Full Text] [Related]
24. Overview of second-generation tyrosine kinase inhibitors for patients with imatinib-resistant chronic myelogenous leukemia.
Ault P
Clin J Oncol Nurs; 2007 Feb; 11(1):125-9. PubMed ID: 17441403
[TBL] [Abstract][Full Text] [Related]
25. Update on the use of imatinib mesylate.
Sawyers CL
Clin Adv Hematol Oncol; 2005 Oct; 3(10):757-8. PubMed ID: 16258483
[No Abstract] [Full Text] [Related]
26. Persistent LYN signaling in imatinib-resistant, BCR-ABL-independent chronic myelogenous leukemia.
O'Hare T; Eide CA; Deininger MW
J Natl Cancer Inst; 2008 Jul; 100(13):908-9. PubMed ID: 18577744
[No Abstract] [Full Text] [Related]
27. Efficacy and tolerance of dasatinib after imatinib failure or intolerance for patients with chronic myeloid leukemia treated in three different hospitals compare well with results achievable in formal clinical trials.
Zackova D; Klamova H; Muzik J; Cmunt E; Racil Z; Machova Polakova K; Dvorakova D; Jurcek T; Razga F; Cetkovsky P; Dusek L; Mayer J
Leuk Lymphoma; 2013 Oct; 54(10):2310-3. PubMed ID: 23373966
[No Abstract] [Full Text] [Related]
28. New generation leukaemia drugs are on their way.
Nelson L
Drug Discov Today; 2004 Sep; 9(17):732-3. PubMed ID: 15450235
[No Abstract] [Full Text] [Related]
29. Glivec and beyond.
Eur J Cancer; 2006 Aug; 42(12):1695. PubMed ID: 16998957
[No Abstract] [Full Text] [Related]
30. A T315I mutation in e19a2 BCR/ABL1 chronic myeloid leukemia responding to dasatinib.
Cea M; Cirmena G; Garuti A; Rocco I; Palermo C; Cagnetta A; Moran E; Colombo N; Grasso R; Fugazza G; Gobbi M; Nencioni A; Ballestrero A; Patrone F
Leuk Res; 2010 Sep; 34(9):e240-2. PubMed ID: 20447687
[No Abstract] [Full Text] [Related]
31. Chronic myeloid leukemia. Introduction.
Frame D
Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S2-3. PubMed ID: 18056928
[No Abstract] [Full Text] [Related]
32. Multitargeted sequential therapy with MK-0457 and dasatinib followed by stem cell transplantation for T315I mutated chronic myeloid leukemia.
Sanchez-Guijo FM; Lopez-Jimenez J; Gonzalez T; Santamaría C; González M; Del Cañizo MC
Leuk Res; 2009 Jun; 33(6):e20-2. PubMed ID: 19038446
[No Abstract] [Full Text] [Related]
33. New agent overcomes resistance to imatinib.
Ahmad K
Lancet Oncol; 2005 Mar; 6(3):137. PubMed ID: 15759363
[No Abstract] [Full Text] [Related]
34. Successful treatment using low-dose dasatinib for chronic myelogenous leukemia in a patient with megakaryoblastic transformation concomitant with myelofibrosis and an extramedullary tumor.
Yamaguchi M; Munemoto S; Kasada A; Murata R; Ueda M
Leuk Res; 2010 Sep; 34(9):e237-9. PubMed ID: 20371117
[No Abstract] [Full Text] [Related]
35. Prevalence of large granular lymphocytosis in patients with chronic myelogenous leukemia (CML) treated with dasatinib.
Valent JN; Schiffer CA
Leuk Res; 2011 Jan; 35(1):e1-3. PubMed ID: 20888043
[No Abstract] [Full Text] [Related]
36. Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia.
Dumitrescu D; Seck C; ten Freyhaus H; Gerhardt F; Erdmann E; Rosenkranz S
Eur Respir J; 2011 Jul; 38(1):218-20. PubMed ID: 21719499
[No Abstract] [Full Text] [Related]
37. Dasatinib induces long-term remission in imatinib-resistant Philadelphia chromosome-positive acute megakaryoblastic leukemia but fails to prevent development of central nervous system progression.
Papageorgiou SG; Pappa V; Economopoulou C; Tsirigotis P; Konsioti F; Ionnidou ED; Chondropoulos S; Vasilatou D; Papageorgiou E; Economopoulos T; Dervenoulas J
Leuk Res; 2010 Sep; 34(9):e254-6. PubMed ID: 20392492
[No Abstract] [Full Text] [Related]
38. Chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation are resistant to dasatinib: is that true for all the patients?
Eskazan AE; Soysal T; Erbilgin Y; Ozbek U; Ferhanoglu B
Leuk Res; 2011 Sep; 35(9):e145-6. PubMed ID: 21605905
[No Abstract] [Full Text] [Related]
39. Successful management of pregnancy occurring in a patient with chronic myeloid leukemia on dasatinib.
Kroll T; Ames MB; Pruett JA; Fenske TS
Leuk Lymphoma; 2010 Sep; 51(9):1751-3. PubMed ID: 20629520
[No Abstract] [Full Text] [Related]
40. Favorable conception and pregnancy involving a male patient affected by chronic myeloid leukemia while taking dasatinib.
Gentile M; Guido M; Lucia E; Vigna E; Mazzone C; Recchia AG; Morabito F
Leuk Lymphoma; 2014 Mar; 55(3):709-10. PubMed ID: 23741978
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
